No Data
Is Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Worth US$2.7 Based On Its Intrinsic Value?
Sonoma Pharmaceuticals GAAP EPS of -$0.63 Beats by $0.06, Revenue of $3.6M Misses by $0.46M
Sonoma Pharmaceuticals | 10-Q: Q3 2025 Earnings Report
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results
Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices
Express News | Sonoma Pharmaceuticals Inc - to Resume Selling Acuicyn, Celacyn, Epicyn, Lasercyn, Levicyn in U.S.
